Strategic focus Accelevir Diagnostics specializes in ultra-rare analytes in infectious disease and translational research, creating opportunities to upsell bespoke assays and scalable workflows to biopharma partners advancing HIV-1 and other chronic viral infections.

Funding momentum With over 15 million in federal, state, and private funding and current revenue in the multi-million range, there is demonstrated investor and customer confidence that can be leveraged to pursue collaboration agreements, co-development deals, and early-access programs.

Partnership potential Active collaboration with leading academic and biopharma groups indicates readiness for sponsored research, contract development and manufacturing, and translational studies that can be expanded to pharma clients seeking novel assay platforms.

Technical footprint Expertise spans virology, immunology, genomics, and cell and gene therapy along with scalable assay workflows, suggesting opportunities to cross-sell comprehensive analytics services, assay validation packages, and regulatory-ready workflows to large life sciences customers.

Growth and readiness Small but growing team with a route to scale positions Accelevir as a nimble partner for early-stage clinical trials and translational research programs, appealing to sponsors needing agile, rapid-turnaround assay development and deployment.